2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
- PMID: 31591002
- DOI: 10.1016/j.atherosclerosis.2019.08.014
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Erratum in
-
Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].Atherosclerosis. 2020 Jan;292:160-162. doi: 10.1016/j.atherosclerosis.2019.11.020. Epub 2019 Dec 4. Atherosclerosis. 2020. PMID: 31811963 No abstract available.
-
Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].Atherosclerosis. 2020 Feb;294:80-82. doi: 10.1016/j.atherosclerosis.2019.12.004. Epub 2019 Dec 20. Atherosclerosis. 2020. PMID: 31870624 No abstract available.
Keywords: Apolipoprotein B; Cholesterol;; Dyslipidaemias; Familial hypercholesterolaemia; Guidelines; High-density lipoproteins; Lipoprotein remnants; Lipoprotein(a); Low-density lipoproteins; Total cardiovascular risk; Treatment (adherence); Treatment (drugs); Treatment (lifestyle); Triglycerides; Very low-density lipoproteins.
Comment in
-
The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.Atherosclerosis. 2020 Jan;292:231-233. doi: 10.1016/j.atherosclerosis.2019.11.009. Epub 2019 Nov 14. Atherosclerosis. 2020. PMID: 31784033 No abstract available.
-
Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: Results from the Rotterdam Study.Atherosclerosis. 2020 Apr;299:64-66. doi: 10.1016/j.atherosclerosis.2020.02.020. Epub 2020 Feb 29. Atherosclerosis. 2020. PMID: 32169303 No abstract available.
-
Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.Atherosclerosis. 2020 Sep;309:67-69. doi: 10.1016/j.atherosclerosis.2020.07.018. Epub 2020 Jul 30. Atherosclerosis. 2020. PMID: 32859385 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical